Article content material
MONTREAL, Sept. 26, 2024 (GLOBE NEWSWIRE) — Epitopea, a transatlantic most cancers immunotherapy firm, and CQDM are proud to announce the launch of a collaborative analysis challenge between Epitopea and Université de Montréal (UdeM), a number one Canadian analysis establishment famend for scientific innovation and know-how switch. Collectively, they may look at the feasibility of creating new immunotherapies to successfully deal with sufferers with lung and ovarian cancers. This collaborative program was made doable by a grant of Canadian $1,499,457 from the federal government of Quebec.
Commercial 2
Article content material
CryptoMapTM is a platform ensuing from the work of Professors Claude Perreault and Pierre Thibault on the Institute for Analysis in Immunology and Most cancers (IRIC) of UdeM. This platform has already allowed identification of non-mutated tumor antigens, uniquely expressed by most cancers cells current in sufferers with the identical sort of most cancers, known as CryptigensTM. Throughout this challenge, novel CryptigenTM units might be recognized from sufferers with numerous origins enabling the creation of common RNA-coding most cancers vaccines concentrating on this new class of antigens. Epitopea will validate this distinctive method to stimulate the immune system to exactly acknowledge and destroy most cancers cells extra quickly and successfully.
This challenge has the potential to ‘unveil’ an unprecedented assortment of CryptigensTM, an method that distinguishes Epitopea from different most cancers vaccine corporations. Primarily based on these knowledge, Epitopea might be positioned to develop new RNA-based immunotherapies from this huge assortment of sufferers samples and advance these modern merchandise into scientific trials. Epitopea’s mission aligns completely with Quebec’s initiatives to develop experience within the discipline of RNA vaccines, as was highlighted within the latest AReNA announcement, Quebec’s new RNA cluster, which goals to place Quebec as a frontrunner in RNA-based therapies(1).
Article content material
Commercial 3
Article content material
“Our authorities is happy to help CQDM’s initiative to facilitate analysis into new RNA-targeting therapies for the therapy of varied types of most cancers. Québec is a worldwide centre for innovation within the life sciences, and we stay dedicated to pushing ahead on behalf of all Quebecers who’re affected by most cancers in a method or one other,” stated Christine Fréchette, Minister of the Economic system, Innovation and Power, Minister answerable for Regional Financial Improvement and Minister answerable for the Better Montreal Space.
“We’re more than happy to accomplice with CQDM, UdeM, and our scientific co-founders, Drs. Perreault and Thibault to additional prolong the affected person inhabitants that would doubtlessly profit from Epitopea’s transformative method to treating most cancers,” commented Epitopea’s CEO, Alan C. Rigby. “Epitopea will initially deploy these CryptigensTM in an off-the-shelf most cancers vaccine method, which we imagine presents important aggressive benefits over personalised most cancers vaccines being developed by many different organizations within the RNA immunotherapy ecosystem. Due to its refined versatility, we imagine that the CryptoMapTM platform developed at UdeM might be utilized to a variety of tumor varieties, positively impacting affected person responses in Quebec and throughout the globe.”
Commercial 4
Article content material
“CQDM is proud to help a challenge that would rework the lives of most cancers sufferers by offering accessible and efficient RNA therapeutic options for difficult-to-treat illnesses. This modern collaboration between the Université de Montréal and Epitopea illustrates Quebec’s dynamism as a world chief in immunotherapy analysis. Not solely will this challenge strengthen our understanding of most cancers remedies, it is going to additionally place Quebec as a key participant within the international vaccine and RNA remedy business,” stated Diane Gosselin, President and CEO of CQDM.
Reference:
(1) https://cqdm.org/en/2024/06/05/quebec-launches-arena-to-become-a-global-leader-in-rna-therapies/
About CQDM
Biopharma innovation facilitator
CQDM is a not-for-profit biopharmaceutical analysis consortium whose mission is to help and facilitate multi-stakeholder collaborative analysis and improvement aimed toward accelerating the interpretation or transformation of modern applied sciences into options for unmet medical wants, whereas producing important spin-offs for the Quebec and Canadian economies. For extra info, go to cqdm.org/ and be a part of us on Twitter/X @CQDM_Canada and LinkedIn.
Commercial 5
Article content material
About Epitopea
Epitopea is a transatlantic most cancers immunotherapeutics firm creating accessible off-the-shelf RNA-based immunotherapies to be used in hard-to-treat cancers by concentrating on a brand new class of untapped tumor-specific antigens, that are generally known as CryptigenTM TSAs, which are broadly shared throughout a number of sufferers with the identical tumor sort.
The corporate has created an intensive library of novel CryptigenTM TSAs, found by its proprietary CryptoMapTM platform that leverages immunopeptidomics, genomics, and a bioinformatics pipeline, permitting the identification of aberrantly-expressed, tumour-specific antigens (aeTSA’s) which are hidden inside most cancers’s ’junk’ DNA. These hidden CryptigenTM TSAs have been first found via analysis led by Drs. Claude Perreault and Pierre Thibault on the Institute for Analysis in Immunology and Most cancers on the Université de Montréal.
Epitopea is backed by main transatlantic life science traders together with Creation Life Sciences, CTI Life Sciences, Cambridge Innovation Capital, Le Fonds de Solidarité FTQ, the Harrington Discovery Institute, Novateur Ventures, and Investissement Québec. The corporate has raised financing of greater than $13 Million USD. Epitopea was based in 2021 and consists of sister corporations primarily based in Cambridge, UK and in Montreal, Canada. For added info, please go to www.epitopea.com/ and observe us on LinkedIn.
Commercial 6
Article content material
About Université de Montréal
Deeply rooted in Montreal and devoted to its worldwide mission, Université de Montréal is a number one analysis college worldwide and among the many 5 finest French-language universities. With its affiliated colleges, Polytechnique Montréal and HEC Montréal, UdeM attracts over $650 million in analysis funding yearly, making it certainly one of Canada’s high college analysis hubs. UdeM has over 67,000 college students, 2,300 professors and researchers, and an lively international community of 450,000 alumni. For added info, please go to: umontreal.ca/
For additional info
Julia Serafino
Advertising and marketing Communication Coordinator
CQDM
Tel: +1 438-543-9498
jserafino@cqdm.org
Geneviève O’Meara
Spokesperson and Senior Advisor
Université de Montréal
Tel: +1 514-343-7704
genevieve.omeara@umontreal.ca
Scius Communications (for Epitopea)
Katja Stout
Tel: +44 7789 435990
katja@sciuscommunications.com
Article content material